Pediatric Gastroenterology and Cystic Fibrosis Unit, Department of Human Pathology in Adulthood and Childhood "G. Barresi", University of Messina, Messina, Italy.
J Clin Pharm Ther. 2022 Feb;47(2):254-256. doi: 10.1111/jcpt.13494. Epub 2021 Jul 18.
The off-label use of vedolizumab (VDZ) for inflammatory bowel disease in children is increasing. We report on possibly the first case of VDZ-associated pulmonary manifestations in paediatrics.
This report details the case of a 13-year-old child with ulcerative colitis who was initiated on VDZ due to persistent active disease. After the first three doses, he developed a persistent and productive cough. Microbiological work-up was normal. VDZ discontinuation led to the resolution of symptoms.
To our knowledge, this is the first case report of VDZ-associated pulmonary manifestations in paediatrics. A direct, pro-inflammatory effect of VDZ has been hypothesized, but further studies are warranted.
vedolizumab（VDZ）在儿童中的非适应证使用用于炎症性肠病的情况正在增加。我们报告儿科中可能首例与 VDZ 相关的肺部表现的病例。
本报告详细介绍了一例溃疡性结肠炎患儿的病例，该患儿因疾病持续活动而开始接受 VDZ 治疗。在接受前三剂治疗后，他出现了持续和多痰的咳嗽。微生物学检查结果正常。停用 VDZ 后症状得到缓解。
据我们所知，这是儿科中首例与 VDZ 相关的肺部表现的病例报告。已假设 VDZ 具有直接的促炎作用，但需要进一步的研究。
